These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33194604)

  • 21. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status.
    Kanat O; Ertas H; Caner B
    World J Clin Cases; 2018 Oct; 6(11):418-425. PubMed ID: 30294606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.
    Li X; Gu X; Xu J; Chen L; Li H; Meng D; Bai H; Yang J; Qian J
    Onco Targets Ther; 2021; 14():3983-3989. PubMed ID: 34234467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
    Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
    Front Oncol; 2020; 10():559057. PubMed ID: 33123470
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
    Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
    Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2-amplified metastatic lung adenocarcinoma responds to fourth-line pyrotinib therapy: A case report.
    Gong K; Yang Y; Huang H; Kuang X; Yang X
    Mol Clin Oncol; 2021 Oct; 15(4):213. PubMed ID: 34476097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib.
    Gao Z; Song C; Li G; Lin H; Lian X; Zhang N; Cao B
    Onco Targets Ther; 2019; 12():2777-2787. PubMed ID: 31114227
    [No Abstract]   [Full Text] [Related]  

  • 30. HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review.
    Chen ML; Yu W; Cui B; Yu Y; Ma Z
    Front Oncol; 2022; 12():980635. PubMed ID: 36741701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.
    Wu J; You Y; Zhuang R; Guo X; Zhang C; Zhang Q; Zhou Y; Li Q
    Ann Transl Med; 2022 Mar; 10(6):387. PubMed ID: 35433993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab.
    Yao JH; Xie ZY; Li M; Zhang ML; Ci HF; Yang Y
    Am J Transl Res; 2020; 12(9):5874-5881. PubMed ID: 33042466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
    Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
    Front Oncol; 2020; 10():811. PubMed ID: 32528890
    [No Abstract]   [Full Text] [Related]  

  • 37. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
    Johnston SR; Leary A
    Drugs Today (Barc); 2006 Jul; 42(7):441-53. PubMed ID: 16894399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.
    Li S; Liu Q; Liu M; Liu T
    Cancer Manag Res; 2022; 14():2927-2932. PubMed ID: 36200096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.
    Sapna F; Athwal PSS; Kumar M; Randhawa S; Kahlon S
    Cureus; 2020 Aug; 12(8):e9522. PubMed ID: 32905036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.